Nature Communications (Jun 2019)

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

  • Richard W. Birkinshaw,
  • Jia-nan Gong,
  • Cindy S. Luo,
  • Daisy Lio,
  • Christine A. White,
  • Mary Ann Anderson,
  • Piers Blombery,
  • Guillaume Lessene,
  • Ian J. Majewski,
  • Rachel Thijssen,
  • Andrew W. Roberts,
  • David C. S. Huang,
  • Peter M. Colman,
  • Peter E. Czabotar

DOI
https://doi.org/10.1038/s41467-019-10363-1
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 10

Abstract

Read online

The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant, revealing the structural basis for venetoclax resistance.